Prestige Consumer Healthcare Inc (NYSE: PBH) is an over-the-counter healthcare company that owns and markets a portfolio of consumer health brands across North American and international markets. It generates revenue through transactional sales of branded OTC products sold to mass merchandisers, drug stores, food retailers, dollar stores, and e-commerce channels. North American OTC Healthcare contributed 83.9% of total revenues in FY2026, with the remaining 16.1% from International OTC Healthcare. Approximately 63.7% of FY2026 revenues came from brands holding the number one market position in their respective categories, including BC and Goody's, Chloraseptic, Compound W, Debrox, Dramamine, Fleet, Gaviscon, Monistat, and Summer's Eve. The company operates a low-cost model built around acquired trademarks, tradenames, and patents, with goodwill and intangible assets comprising the majority of total assets. PBH does not pay cash dividends. Ronald M. Lombardi serves as President and CEO, and Christine Sacco serves as CFO and COO, as of the 10-K filed May 14, 2026.

Revenue model

Transactional sales of branded OTC consumer healthcare products through retail and e-commerce channels. No subscription or licensing revenue model is disclosed. Products are manufactured by third-party contract manufacturers and sold through a direct sales force and third-party sales management enterprises.

Products and services

Branded OTC healthcare products across analgesics (BC, Goody's), sore throat (Chloraseptic), wart removal (Compound W), ear care (Debrox), motion sickness (Dramamine), laxatives (Fleet), heartburn (Gaviscon), oral hydration (Hydralyte), feminine health (Monistat, Summer's Eve), lice treatment (Nix), eye care (Clear Eyes), baby skin care (Boudreaux's Butt Paste), and respiratory (Fess). In FY2026, brands with a number one market position represented 63.7% of total revenues.

Customers and end markets

End consumers purchasing OTC healthcare products for recurring self-care needs. Trade customers include mass merchandisers (35.0% of U.S. gross revenues in FY2026), drug and drug wholesale (19.2%), food retailers (12.6%), dollar stores (5.4%), convenience stores (3.1%), club stores (0.6%), and other channels including e-commerce such as Amazon (24.1%). Figures are for the fiscal year ended March 31, 2026.

Value-chain role

Brand owner and marketer. PBH acquires, owns, and supports consumer brands while outsourcing physical manufacturing to third-party contract manufacturers. It maintains a direct sales force and also contracts with third-party sales management enterprises for customer coverage across retail channels.

Geographic exposure

Two reportable segments as of FY2026: North American OTC Healthcare (83.9% of revenues) and International OTC Healthcare (16.1% of revenues), per the 10-K filed May 14, 2026.

Competitors

Church & Dwight Co., Inc., Edgewell Personal Care Company, Energizer Holdings, Inc., Helen of Troy, Ltd., Spectrum Brands Holdings

Source: SEC 10-K, filed 2026-05-14

Industry: Pharmaceutical Preparations Peers: Arvinas Inc Pacira Biosciences Inc CORCEPT THERAPEUTICS INC Elanco Animal Health Inc Harmony Biosciences Holdings Inc Intra-Cellular Therapies, Inc. Johnson & Johnson